Related Experiment Video
Updated: Jun 17, 2025
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
A case report and literature review on TP53 gene mutation in a bladder rhabdomyosarcoma patient
Yixuan Li1, Tianci Yang1, Zhouhang Zheng1
1The Second Clinical Medical School, Lanzhou University, Lanzhou, China.
Background:
Rhabdomyosarcoma of the bladder is an infrequent neoplastic condition characterized by a pronounced malignant situation with challenges in treatment due to the lack of standardized guidelines and large-scale of clinical studies. The patient in this case is tested TP53 mutation that may provide new diagnostic and therapeutic options.
Case Presentation:
Here, we reported a 34-year-old male who received bladder tumor resection, and diagnosed as bladder rhabdomyosarcoma with TP53 mutation after the pathology test. This patient underwent 6 rounds of chemotherapy. However, the pelvic tumor recurred 11 months after the first surgery. So, the patient accepted the pelvic tumor resection. Only 3 months after the surgical intervention, the patient underwent abdominal massive metastasis and ultimately succumbed to the illness six months following the second surgery. The course of the illness was 22 months.
Conclusion:
Bladder rhabdomyosarcoma is a disease with an extremely poor prognosis. Genetic testing holds significant value in the diagnosis and treatment. Perhaps targeted therapy against TP53 is potential valuable for such rare diseases.
Insights
Bladder rhabdomyosarcoma is rare and aggressive. TP53 gene mutations may offer new diagnostic and therapeutic avenues for this challenging cancer.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Bladder rhabdomyosarcoma is a rare and aggressive malignancy.
- Limited standardized treatment guidelines and clinical studies pose significant challenges.
- The TP53 mutation presents potential diagnostic and therapeutic opportunities.
Observation:
- A 34-year-old male diagnosed with bladder rhabdomyosarcoma and a TP53 mutation after tumor resection.
- The patient experienced tumor recurrence 11 months post-initial surgery, followed by a second resection.
- Despite treatment, the patient developed widespread metastasis and succumbed to the illness 22 months after initial diagnosis.
Findings:
- Bladder rhabdomyosarcoma carries an extremely poor prognosis.
- Genetic testing, specifically for TP53 mutations, is crucial for diagnosis and treatment planning.
- The identified TP53 mutation in this case highlights its potential role in disease progression.
Implications:
- Targeted therapies focusing on TP53 mutations may offer a novel treatment strategy.
- Further research into genetic alterations in bladder rhabdomyosarcoma is warranted.
- This case underscores the importance of integrating genetic profiling into the management of rare cancers.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...